Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

about

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Tumour necrosis factor antagonist-induced lupus: a Critically Appraised Topic.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.

P2860

Q38642378-2937D117-BEFC-465D-9521-9F38CB8E03C2 Q48298265-8242E0FF-47EC-4BA3-84AF-82C8090C65D9 Q50083992-321F7BBF-DE7F-400B-9AAA-2494582907D5

P2860

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

Item

http://www.wikidata.org/entity/Q37599165

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Drug-specific risk and charact ...... h TNFi: results from BSRBR-RA.

@en

Drug-specific risk and charact ...... h TNFi: results from BSRBR-RA.

@nl

type

Item

label

Drug-specific risk and charact ...... h TNFi: results from BSRBR-RA.

@en

Drug-specific risk and charact ...... h TNFi: results from BSRBR-RA.

@nl

prefLabel

Drug-specific risk and charact ...... h TNFi: results from BSRBR-RA.

@en

Drug-specific risk and charact ...... h TNFi: results from BSRBR-RA.

@nl

P1154

2-s2.0-85013867654

http://www.w3.org/2001/XMLSchema#string

P1433

RMD open

P1476

Drug-specific risk and charact ...... h TNFi: results from BSRBR-RA.

@en

P2093

BSRBR-RA Control Centre Consortium*

http://www.w3.org/2001/XMLSchema#string

BSRBR-RA*

http://www.w3.org/2001/XMLSchema#string

Kath Watson

http://www.w3.org/2001/XMLSchema#string

Kimme L Hyrich

http://www.w3.org/2001/XMLSchema#string

Mark Lunt

http://www.w3.org/2001/XMLSchema#string

P2507

Correction: Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA

P2860

Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.

Drug-induced lupus due to anti-tumor necrosis factor alpha agents.

P304

e000314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/RMDOPEN-2016-000314

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lianne Kearsley-Fleet

P5530

15839834

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1079402101

http://www.w3.org/2001/XMLSchema#string

P6409

74196394

http://www.w3.org/2001/XMLSchema#string

P698

28123776

http://www.w3.org/2001/XMLSchema#string

P932

5255894

http://www.w3.org/2001/XMLSchema#string

P953

115260/